GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

SymBio Obtains Rights to Leukemia Drug Candidate

  • SymBio Pharmaceuticals obtained rights to a drug that’s touted to have therapeutic potential to treat Gleevec-resistant chronic myeloid leukemia and mast cell leukemia.

    PEG-ZnPP was developed by Hiroshi Maeda and fellow researchers at Sojo University. According to Maeda, PEG-ZnPP exhibits an inhibitory antitumor effect on heme oxygenase activity, leading to an increase in the production of toxic oxidants and eventual cancer cell death.

    This exclusive global license adds a third clinical candidation to SymBio’s pipeline.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?